ADVERTISEMENT

Conference Report

Baxdrostat Slashes BP in Resistant Hypertension: BrigHTN

Patrice Wendling   |   14 November 2022
View more articles on:

An investigational aldosterone synthase inhibitor could be an effective new treatment to reduce blood pressure in patients with treatment-resistant hypertension, a phase 2 study suggests.

The BrigHTN trial showed systolic blood pressure fell by an average of 20.3 mm Hg, 17.5 mm Hg, and 12.1 mm Hg with baxdrostat 2 mg, 1...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right